We have developed a chaperoning technology built on the superior protein antigen-holding feature of large chaperone molecules (Hsp110, Grp170) to construct synthetic chaperone complex vaccines targeting specific tumor antigens (e.g., Gp100) [14]. This evidence concerns the gene HSPH1 and neoplasm.